Sex: F
Vaccine: FLUX, HPV4, MNQ
Symptoms: Generalised tonic-clonic seizure, Glutathione decreased, Hallucination, Irritability, Loss of consciousness
Clinical narrative: This case was reported by a other health professional and described the occurrence of seizure in a female patient who received Men ACWY-CRM NVS (Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine) for prophylaxis. Co-suspect products included Flu unspecified (Influenza vaccine) for prophylaxis and Gardasil unknown for product used for unknown indication. Concomitant products included budesonide, montelukast sodium (Montelukast) and salmeterol xinafoate. On 19th November 2008, the patient received Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine (intramuscular), Influenza vaccine (intramuscular) .5 ml and GARDASIL (intramuscular) at an unknown dose and frequency. On 19th October 1011, 2 years and 334 days after receiving Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine and Influenza vaccine, the patient experienced abnormal electroencephalogram (serious criteria disability and life threatening). On 1st January 2010, the patient experienced tonic-clonic seizures (serious criteria disability, GSK medically significant and life threatening), absence seizure (serious criteria disability, GSK medically significant and life threatening), fatigue extreme (serious criteria disability and life threatening), feeling cold (serious criteria disability and life threatening), stress (serious criteria disability and life threatening), acne (serious criteria disability and life threatening), irritability (serious criteria disability and life threatening), sinus infection (serious criteria disability and life threatening), stereotypy (serious criteria disability and life threatening), sleep walking (serious criteria disability and life threatening), shaking of hands (serious criteria disability and life threatening), pain (serious criteria disability and life threatening), memory loss (serious criteria disability and life threatening), anxiety (serious criteria disability and life threatening), hallucination (serious criteria disability and life threatening) and visual impairment (serious criteria disability and life threatening). On 10th October 2011, the patient experienced nuclear magnetic resonance imaging abnormal (serious criteria disability and life threatening) and scan with contrast abnormal (serious criteria disability and life threatening). On 19th October 2011, the patient experienced epilepsy (serious criteria disability, GSK medically significant and life threatening). On 23rd February 2012, the patient experienced neutrophil count decreased (serious criteria disability and life threatening), estradiol increased (serious criteria disability and life threatening), eosinophil count high (serious criteria disability and life threatening) and progesterone decreased (serious criteria disability and life threatening). On 30th April 2012, the patient experienced glutathione decreased (serious criteria disability and life threatening). On 28th June 2012, the patient experienced lymphadenopathy axillary (serious criteria disability and life threatening). On an unknown date, the patient experienced seizure (serious criteria disability, GSK medically significant and life threatening), stiffness (serious criteria disability and life threatening), blackout (serious criteria disability, GSK medically significant and life threatening), confusion (serious criteria disability and life threatening) and gene mutation (serious criteria disability and life threatening). On an unknown date, the outcome of the seizure, tonic-clonic seizures, absence seizure, epilepsy, neutrophil count decreased, fatigue extreme, feeling cold, stiffness, stress, glutathione decreased, acne, blackout, abnormal electroencephalogram, irritability, sinus infection, estradiol increased, stereotypy, sleep walking, confusion, shaking of hands, nuclear magnetic resonance imaging abnormal, pain, eosinophil count high, memory loss, anxiety, scan with contrast abnormal, gene mutation, hallucination, progesterone decreased, visual impairment and lymphadenopathy axillary were not recovered/not resolved. It was unknown if the reporter considered the seizure, tonic-clonic seizures, absence seizure, epilepsy, neutrophil count decreased, fatigue extreme, feeling cold, stiffness, stress, glutathione decreased, acne, blackout, abnormal electroencephalogram, irritability, sinus infection, estradiol increased, stereotypy, sleep walking, confusion, shaking of hands, nuclear magnetic resonance imaging abnormal, pain, eosinophil count high, memory loss, anxiety, scan with contrast abnormal, gene mutation, hallucination, progesterone decreased, visual impairment and lymphadenopathy axillary to be related to Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine and Influenza vaccine. Additional details: Age at vaccination was not reported. Initial information was reported by a other health professional on 25th march 2019: Epilepsy, neutrophils reduced, fatigue extreme, feeling cold, stiffness, stress, glutathione decreased, acne, eeg abnormal, irritability, sinus infection, estradiol increased, blackout, stereotypy, sleep walking, confusion, seizures, tonic-clonic seizures, shaking of hands, nuclear magnetic resonance imaging abnormal, absence seizure, pain, eosinophil count high, memory loss, anxiety, scan with contrast abnormal, gene mutation, hallucination, progesterone decreased, visual impairment and lymphadenopathy axillary. Lab Comments: on 10th October 2011, scan with contrast test was done with result abnormal.